http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CO-6220945-A2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a5ffa3f9d6b87e15e0a1551fb129b531 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2300-00 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-1623 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-167 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-57 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0075 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-008 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-167 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-57 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P11-06 |
| filingDate | 2009-10-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_61a666b4c84cf155798374150f9eb2f9 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_63b926b97e55b8ca4890a518f6fc8930 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e27622fdc951584955d09e5649e14147 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_19e16676a77164ad4ada4fe3e2fe845c |
| publicationDate | 2010-11-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CO-6220945-A2 |
| titleOfInvention | USE OF A COMPOSITION THAT INCLUDES FORMOTEROL AND DIPROPIANATE OF BECLOMETASONE FOR THE PREVENTION AND / OR TREATMENT OF AN EXAMERATION OF ASTHMA |
| abstract | 1. The use of a composition comprising a fixed combination of a) formoterol, a pharmaceutically acceptable salt or solvate of such salt; and b) beclomethasone dipropionate; for the manufacture of a medicament for use in the prevention and / or treatment of an exacerbation of asthma, intermittent asthma and / or episodes in chronic asthma during asthma maintenance therapy with the same composition for symptomatic relief, when necessary. 2. The use according to claim 1, wherein the molar ratio of (a) with respect to (b), calculated as formoterol with respect to beclomethasone dipropionate, is from 1: 1 to 1: 500.3.- The use according to claim 2, wherein the molar ratio of (a) with respect to (b), calculated as formoterol with respect to beclomethasone dipropionate, is from 1: 1 to 1: 100. 4. The use according to claim 3, wherein the molar ratio of (a) with respect to (b), calculated as formoterol with respect to beclomethasone dipropionate, is from 1: 3 to 1:30. 5. The use according to claim 4, wherein the molar ratio of (a) with respect to (b), calculated as formoterol with respect to beclomethasone dipropionate, is 1: 12.8. 6. The use according to claim 4, wherein the molar ratio of (a) with respect to (b), calculated as formoterol with respect to beclomethasone dipropionate, is 1: 25.6. 7. The use according to any of claims 1 to 6 wherein the first active ingredient is formoterol fumarate dihydrate. 8. The use according to any of claims 1 to 6 wherein the first active ingredient is the R-enantiomer, R formoterol or pharmaceutically acceptable salt or solvate thereof or a solvate of such salt. 9. The use according to any of the preceding claims wherein the daily dose of formoterol for adults, including maintenance therapy, can be as high as 168 micrograms, preferably 100 micrograms, and more preferably 84 micrograms and even more preferably 72 micrograms |
| priorityDate | 2007-04-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 32.